Literature DB >> 9869386

Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography.

M Kosel1, C B Eap, M Amey, P Baumann.   

Abstract

A procedure using a chirobiotic V column is presented which allows separation of the enantiomers of citalopram and its two N-demethylated metabolites, and of the internal standard, alprenolol, in human plasma. Citalopram, demethylcitalopram and didemethylcitalopram, as well as the internal standard, were recovered from plasma by liquid-liquid extraction. The limits of quantification were found to be 5 ng/ml for each enantiomer of citalopram and demethylcitalopram, and 7.5 ng/ml for each enantiomer of didemethylcitalopram. Inter- and intra-day coefficients of variation varied from 2.4% to 8.6% for S- and R-citalopram, from 2.9% to 7.4% for S- and R-demethylcitalopram, and from 5.6% to 12.4% for S- and R- didemethylcitalopram. No interference was observed from endogenous compounds following the extraction of plasma samples from 10 different patients treated with citalopram. This method allows accurate quantification for each enantiomer and is, therefore, well suited for pharmacokinetic and drug interaction investigations. The presented method replaces a previously described highly sensitive and selective high-performance liquid chromatography procedure using an acetylated 3-cyclobond column which, because of manufactural problems, is no longer usable for the separation of the enantiomers of citalopram and its demethylated metabolites.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9869386     DOI: 10.1016/s0378-4347(98)00384-3

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  6 in total

Review 1.  Considerations on HILIC and polar organic solvent-based separations: use of cyclodextrin and macrocyclic glycopetide stationary phases.

Authors:  Chunlei Wang; Chunxia Jiang; Daniel W Armstrong
Journal:  J Sep Sci       Date:  2008-06       Impact factor: 3.645

2.  Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response.

Authors:  Georg Nikisch; Aleksander A Mathé; Adelheid Czernik; Jutta Thiele; Jürgen Bohner; Chin B Eap; Hans Agren; Pierre Baumann
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

3.  Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors.

Authors:  I Ceglia; S Acconcia; C Fracasso; M Colovic; S Caccia; R W Invernizzi
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

4.  Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes.

Authors:  Karin Herrlin; Norio Yasui-Furukori; Gunnel Tybring; Jolanta Widén; Lars L Gustafsson; Leif Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

5.  Spectrofluorimetric method for determination of citalopram in bulk and pharmaceutical dosage forms.

Authors:  S G Vasantharaju; S Lakshmana Prabu; A Jacob
Journal:  Indian J Pharm Sci       Date:  2008-09       Impact factor: 0.975

6.  Enantioseparation of Citalopram by RP-HPLC, Using Sulfobutyl Ether-β-Cyclodextrin as a Chiral Mobile Phase Additive.

Authors:  Yangfeng Peng; Quan Sophia He; Jiang Cai
Journal:  Int J Anal Chem       Date:  2016-01-05       Impact factor: 1.885

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.